Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

被引：88
|
作者：
Yee, Sook Wah [1 ,2 ]
Brackman, Deanna J. [1 ,2 ]
Ennis, Elizabeth A. [1 ,2 ]
Sugiyama, Yuichi [3 ]
Kamdem, Landry K. [4 ]
Blanchard, Rebecca [5 ]
Galetin, Aleksandra [6 ]
Zhang, Lei [7 ]
Giacomini, Kathleen M. [1 ,2 ,8 ]
机构：
[1] Univ Calif San Francisco, Sch Pharm, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Sch Med, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[3] RIKEN, Res Cluster Innovat, RIKEN Innovat Ctr, Sugiyama Lab, Yokohama, Kanagawa, Japan
[4] Harding Univ, Coll Pharm, Dept Pharmaceut Sci, Searcy, AR USA
[5] CRISPR Therapeut, Cambridge, MA USA
[6] Univ Manchester, Sch Hlth Sci, Ctr Appl Pharmacokinet Res, Manchester, Lancs, England
[7] US FDA, Off Res & Stand, Off Gener Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[8] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 104卷 / 05期
关键词：
D O I：
10.1002/cpt.1098
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Advances in genomic technologies have led to a wealth of information identifying genetic polymorphisms in membrane transporters, specifically how these polymorphisms affect drug disposition and response. This review describes the current perspective of the International Transporter Consortium(ITC) on clinically important polymorphisms in membrane transporters. ITC suggests that, in addition to previously recommended polymorphisms in ABCG2 (BCRP) and SLCO1B1 (OATP1B1), polymorphisms in the emerging transporter, SLC22A1 (OCT1), be considered during drug development. Collectively, polymorphisms in these transporters are important determinants of interindividual differences in the levels, toxicities, and response to many drugs.
引用
收藏
页码：803 / 817
页数：15
相关论文
共 50 条
  • [31] Effects of ABCB1 drug transporter genotypes on antiepileptic drug disposition
    Lovric, M.
    Bozina, N.
    Hajnsek, S.
    Sporis, D.
    Lalic, Z.
    Granic, P.
    THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 509 - 509
  • [32] Intestinal P-gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications
    Zamek-Gliszczynski, Maciej J.
    Patel, Mitesh
    Yang, Xinning
    Lutz, Justin D.
    Chu, Xiaoyan
    Brouwer, Kim L. R.
    Lai, Yurong
    Lee, Caroline A.
    Neuhoff, Sibylle
    Paine, Mary F.
    Sugiyama, Yuichi
    Taskar, Kunal S.
    Galetin, Aleksandra
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (01) : 55 - 64
  • [33] Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective
    Kenna, J. Gerry
    Taskar, Kunal S.
    Battista, Christina
    Bourdet, David L.
    Brouwer, Kim L. R.
    Brouwer, Kenneth R.
    Dai, David
    Funk, Christoph
    Hafey, Michael J.
    Lai, Yurong
    Maher, Jonathan
    Pak, Y. Anne
    Pedersen, Jenny M.
    Polli, Joseph W.
    Rodrigues, A. David
    Watkins, Paul B.
    Yang, Kyunghee
    Yucha, Robert W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) : 916 - 932
  • [34] Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective
    Taskar, Kunal S.
    Yang, Xinning
    Neuhoff, Sibylle
    Patel, Mitesh
    Yoshida, Kenta
    Paine, Mary F.
    Brouwer, Kim L. R.
    Chu, Xiaoyan
    Sugiyama, Yuichi
    Cook, Jack
    Polli, Joseph W.
    Hanna, Imad
    Lai, Yurong
    Zamek-Gliszczynski, Maciej
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (03) : 573 - 592
  • [35] Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions
    Gharavi, Robert
    Hedrich, William
    Wang, Hongbing
    Hassan, Hazem E.
    PHARMACEUTICAL RESEARCH, 2015, 32 (08) : 2477 - 2502
  • [36] Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions
    Robert Gharavi
    William Hedrich
    Hongbing Wang
    Hazem E. Hassan
    Pharmaceutical Research, 2015, 32 : 2477 - 2502
  • [37] A pharmaceutical industry perspective on transporter and CYP-mediated drug-drug interactions: kidney transporter biomarkers
    Shen, Hong
    BIOANALYSIS, 2018, 10 (09) : 625 - 631
  • [38] Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption
    Custodio, Joseph M.
    Wu, Chi-Yuan
    Benet, Leslie Z.
    ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (06) : 717 - 733
  • [39] Polymorphisms in the Drug Transporter Gene ABCB1 Are Associated with Drug Response in Saudi Epileptic Pediatric Patients
    Magadmi, Rania
    Alyoubi, Reem
    Moshrif, Tahani
    Bakhshwin, Duaa
    Suliman, Bandar A.
    Kamel, Fatemah
    Jamal, Maha
    Burzangi, Abdulhadi S.
    Basit, Sulman
    BIOMEDICINES, 2023, 11 (09)
  • [40] Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression
    Uhr, Manfred
    Tontsch, Alina
    Namendorf, Christian
    Ripke, Stephan
    Lucae, Susanne
    Ising, Marcus
    Dose, Tatjana
    Ebinger, Martin
    Rosenhagen, Marcus
    Kohli, Martin
    Kloiber, Stefan
    Salyakina, Daria
    Bettecken, Thomas
    Specht, Michael
    Puetz, Benno
    Binder, Elisabeth B.
    Mueller-Myhsok, Bertram
    Holsboer, Florian
    NEURON, 2008, 57 (02) : 203 - 209
12345